Archive




Volume 5, Issue 2, March 2017, Page: 44-49
Expression of Transforming Growth Factorα and Epidermal Growth Factor Receptor in Thyroid Carcinoma
Tahani Abduljabbar Nasser, Department of Biology, College of Science, Wasit University, Wasit, Iraq
Kareem Hamed Ghali, Department of Biology, College of Science, Wasit University, Wasit, Iraq
Hameed Naeem Mousa, Department of Pathology and Forensic Medicine, College of Medicine, Thi Qar University, Thi Qar, Iraq
Received: Jan. 17, 2017;       Accepted: Feb. 18, 2017;       Published: Mar. 9, 2017
DOI: 10.11648/j.ajhr.20170502.14      View  1887      Downloads  128
Abstract
The current study was performed on 178 paraffin embedded tissue specimens, included 111 of them were affected by thyroid carcinoma, 46 were benign neoplastic and 21individuals as control group. The study was carried out in Laboratory of College of Science, University of Wasit in collaboration with AL-Hussein Teaching Hospital and Ibn al-Bitar Laboratory Specialist in Thi Qar Province, IRAQ, from October 2015 to April 2016. Immunohistochemical technique was used to determination the expression of TGFα and its receptor EGFR in thyroid carcinoma in comparison with benign thyroid disease and control group. The aim of this study is to detect, quantify and analyze the clinicopathological correlation of those genes in patients with thyroid carcinoma. The results showed a significant increase of TGFα in thyroid patients comparing with control group and benign neoplasms, and between control group and benign neoplasms (p<0.05). On the other hand, the positive expression of EGFR was increased but did not reach to significantly difference in thyroid carcinoma in comparison with neither benign neoplasms nor control group (p>0.05). Our results concluded that there is a strong relationship between TGFα overexpression with thyroid carcinogenesis.
Keywords
Thyroid Cancer, TGFα, EGFR and Immunohistochemistry
To cite this article
Tahani Abduljabbar Nasser, Kareem Hamed Ghali, Hameed Naeem Mousa, Expression of Transforming Growth Factorα and Epidermal Growth Factor Receptor in Thyroid Carcinoma, American Journal of Health Research. Vol. 5, No. 2, 2017, pp. 44-49. doi: 10.11648/j.ajhr.20170502.14
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Nguyen, Q. T.; Lee, E. J.; Huang, M. G.; Park, Y. I.; Khullar, A. and Plodkowsk, R. A. (2015). Diagnosis and treatment of patients with thyroid cancer, American health & drug benefits, 8 (1), 30-38.
[2]
Khatawkar, A. V. and Awati, S. M. (2015). Thyroid gland - historical, aspects, embryology anatomy and physiology, International Archives of Integrated Medicine, 2 (9).
[3]
Sipos, J. A. and Mazzaferri, E. L. (2010). Thyroid cancer epidemiology and prognostic variables, Clinical Oncology, 22 (6), 395–404.
[4]
Jemal, A.; Siegel, R.; Xu, J. and Ward, E. (2010). Cancer statistics, 2010, CA: a cancer journal for clinicians, 60 (5), 277-300.
[5]
Al Shahrani, A. S.; El-Metwally, A.; Al-Surimi, K.; Bin-Salih, S.; Saleh, Y.; Al-Shehri, A. and Ali, A. (2016). The epidemiology of thyroid diseases in the Arab world: a systematic review, Journal of Public Health and Epidemiology, 8 (2), 17-26.
[6]
Hussain, F.; Iqbal, S.; Mehmood, A.; Bazarbashi, S.; El-Hassan, T. and Chaudhri, N. (2013). Incidence of thyroid cancer in the Kingdom of Saudi Arabia, 2000–2010, Hematology/Oncology and Stem Cell Therapy, 6 (2), 58-64.
[7]
Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D. and Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, 136 (5), 359-386.
[8]
National Cancer Institute (U. S.) (2015). SEER, Surveillance, Epidemiology, and End Results: thyroid cancer, U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
[9]
Shrivastava, J. P.; Mangal, K. S.; Woike, P.; Marskole, P. and Gaur, R. (2016). Role of FNAC in diagnosing thyroid neoplasms – a retrospective study, IOSR Journal of Dental and Medical Sciences, 15 (1), 13-16.
[10]
Trigo, J. M.; Capdevila, J.; Grande, E.; Grau, J. and Lianes, P. (2014). Thyroid cancer: SEOM clinical guidelines, Clinical and Translational Oncology, 16 (12), 1035-1042.
[11]
Mazzaferri, E. L.; Harmer, C.; Mallick, U. K. and Taylor, P. K. (2006). Practical management of thyroid cancer: a multidisciplinary approach. Springer-Verlag, London.
[12]
Herbst, R. S. (2004). Review of epidermal growth factor receptor biology, International Journal of Radiation Oncology, Biology, Physics: Supplement, 59 (2), 21-26.
[13]
Udart, Martin; U., Jochen; K., Gertraud M. and Peter, R. U. (2001). Chromosome 7. Aneusomy. A marker for metastatic melanoma: expression of the epidermal growth factor receptor gene and chromosome 7. Aneusomy in Nevi, primary malignant melanomas and metastases, Nature Publishing Group, 3 (3), 245-254.
[14]
Robinson D. R.; Wu, Y. and Lin, S. (2000). The protein tyrosine kinase family of the human genome, Oncogene, 19 (49), 5548-5557.
[15]
Normanno, N.; De-Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M. R.; Carotenuto, A.; De Feo, G.; Caponigro, F. and S., David S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer, Gene, 366 (1), 2-16.
[16]
Bogdan, S. and Klambt, C. (2001). Epidermal growth factor receptor signaling, Current biology, 11 (8), 292-295.
[17]
Rosenbloom, K. R.; Armstrong, J.; Barber, G. P.; Casper, J. and Clawson, H. (2015). The UCSC genome browser database: 2015 update, Nucleic acids research, 43, 670-681.
[18]
Wieduwilt, M. J. and Moasser, M. M. (2008). The epidermal growth factor receptor family: Biology driving targeted therapeutics, Cellular and molecular life sciences, 65 (10), 1566-1584
[19]
Acton, Q. A. (2013). Gastrointestinal hormone receptors: advances in research and application, Atlanta, Georgia.
[20]
Jameson, J. L.; DeGroot, L. J.; De Kretser, D. M.; Giudice, L.; Grossman, A.; Melmed, S.; Potts, J. T. and Weir, G. C. (2016). Endocrinology: adult & pediatric, 7th edition, Elsevier/Saunders Philadelphia, PA.
[21]
Croyle, M.; Akeno, N.; Knauf, J. A.; Fabbro, D.; Chen, X.; Baumgartner, J. E.; Lane, H. A. and Fagin, J. A. (2008). RET/PTC induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR, Cancer Research, 68 (11), 4183-4191.
[22]
Sethi, K.; Sarkar, S.; Das, S.; Mohanty, B. and Mandal, M. (2010). Biomarkers for the diagnosis of thyroid cancer, Journal of Experimental Therapeutics & Oncology, 8 (4), 341-52.
[23]
Lam, A. K.; Lau, K. K.; Gopalan, V.; Luk, J. and Lo, C. Y. (2011). Quantitative analysis of the expression of transformation growth factor alpha (TGF- α) and epidermal growth factor receptor (EGFR) in papillary thyroid carcinoma: clinicopathological relevance, Pathology, 43 (1), 40–47.
[24]
Lau, K. P. (2007). Clinicopathological Roles of Transforming Growth Factor Alpha (TGFα) in Papillary Thyroid Carcinoma, Hong Kong University Theses Online.
[25]
Daveau, M.; Scotte, M.; FrançOis, A.; Coulouarn, C.; Ros, G.; Tallet, Y.; Hiron, M.; Hellot, M. -F. and Salier, J. P. (2003). Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma, Molecular Carcinogenesis, 36 (3), 130-141.
[26]
Fan, C. Y.; Melhem, M. F.; Hosal, A. s.; Grandis, J. r. and Barnes, E. l. (2001). Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma, Archives of Otolaryngology Head & Neck Surgery, 127 (9), 1075-1079.
[27]
Konturek, P. C.; Konturek, S. J.; Sulekova, Z.; Meixner, H.; Bielanski, W.; Starzynska, T.; Karczewska, E.; Marlicz, K.; Stachura, J. and Hahn, E. g. (2001). Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer, Alimentary Pharmacology & Therapeutics, 15 (7), 989-999.
[28]
Gong, L.; Chen, P.; Liu, X.; Han, Y.; Zhou, Y.; Zhang, W.; Li, H.; Li, C. and Xie, J. (2012). Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma, Gland Surg, 1 (1), 25–32.
Browse journals by subject